当前位置:主页 > 医学论文 > 心血管论文 >

大剂量维生素C辅助免疫球蛋白对感染病毒性心肌炎患者ICAM-1与MIP-1α及NGF的影响研究

发布时间:2018-10-17 08:00
【摘要】:目的探讨大剂量维生素C辅助免疫球蛋白对感染病毒性心肌炎(VMC)患者细胞间黏附因子-1(ICAM-1)、人巨噬细胞炎性蛋白1α(MIP-1α)及神经生长因子(NGF)的影响。方法选取2015年5月-2016年5月医院收治的54例原发性感染性VMC患者,随机分为治疗组及对照组,每组各27例;均予以吸氧、抗病毒、心肌代谢改善等常规治疗,治疗组予以大剂量维生素C联合免疫球蛋白治疗,对照组予以免疫球蛋白治疗;检测血清中ICAM-1、MIP-1α及NGF测定相关心肌酶谱指标,观察临床疗效并进行评价。结果治疗后,两组血清ICAM-1、MIP-1α、NGF水平、心肌酶谱肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LDH)水平较治疗前均明显降低(P0.05);且治疗组ICAM-1、MIP-1α、NGF水平、心肌酶谱CK、CK-MB、LDH水平与对照组比较均明显较低(P0.05);对照组总有效率为81.48%,低于治疗组总有效率为96.30%(P0.05)。结论大剂量维生素C辅助免疫球蛋白对治疗病毒感染性心肌炎疗效显著,安全性高,无显著不良反应发生,且血清ICAM-1、MIP-1α及NGF作为新靶点,可为临床诊疗提供新的思路,值得临床的进一步推广与探讨。
[Abstract]:Objective to investigate the effects of high dose vitamin C adjuvant immunoglobulin on intercellular adhesion factor-1 (ICAM-1), human macrophage inflammatory protein 1 伪 (MIP-1 伪) and nerve growth factor (NGF) (NGF) in patients with viral myocarditis (VMC). Methods from May 2015 to May 2016, 54 patients with primary infectious VMC were randomly divided into treatment group (n = 27) and control group (n = 27). The treatment group was treated with high dose vitamin C combined with immunoglobulin, the control group was treated with immunoglobulin, and the serum ICAM-1,MIP-1 伪 and NGF were measured to determine the related myocardial enzymes, and the clinical efficacy was observed and evaluated. Results after treatment, the levels of serum ICAM-1,MIP-1 伪, NGF, myocardial creatine kinase (CK), creatine kinase isoenzyme (CK-MB) and lactate dehydrogenase (LDH) in both groups were significantly lower than those before treatment (P0.05), and the levels of ICAM-1,MIP-1 伪, NGF in treatment group were significantly lower than those before treatment (P0.05). Compared with the control group, the level of myocardial enzyme CK,CK-MB,LDH was significantly lower (P0.05), the total effective rate of the control group was 81.48, lower than that of the treatment group was 96.30% (P0.05). Conclusion High dose vitamin C immunoglobulin is effective and safe in the treatment of viral myocarditis, and serum ICAM-1,MIP-1 伪 and NGF as new targets can provide new ideas for clinical diagnosis and treatment. It is worthy of further clinical promotion and discussion.
【作者单位】: 台州市中心医院心内科;
【基金】:浙江省医药卫生科技计划基金资助项目(JQ003224)
【分类号】:R542.21

【相似文献】

相关期刊论文 前10条

1 Mol PG ,李文馨;免疫球蛋白治疗慢性特发性血小板减少性紫癜[J];青岛医学院学报;1986年01期

2 杨彩风;免疫球蛋白G治疗小儿重度原发性血小板减少性紫癜[J];山西临床医药;1997年01期

3 张美娱,胡彩华,季美华;大剂量丙种免疫球蛋白治疗特发性血小板减少性紫癜效果观察[J];南通医学院学报;2000年02期

4 张峰,候明;免疫球蛋白治疗特发性血小板减少性紫癜机制的研究进展[J];血栓与止血学;2004年04期

5 马红丽;丁琪;刘瑞玲;;抗-D免疫球蛋白治疗免疫性血小板减少性紫癜的研究进展[J];医学研究杂志;2009年11期

6 冯慧敏;;免疫球蛋白[J];国外医学参考资料(内科学分册);1978年03期

7 李峻亨;吸烟与免疫球蛋白水平[J];北京医学;1979年04期

8 章晓,

本文编号:2276026


资料下载
论文发表

本文链接:https://www.wllwen.com/yixuelunwen/xxg/2276026.html


Copyright(c)文论论文网All Rights Reserved | 网站地图 |

版权申明:资料由用户c2b61***提供,本站仅收录摘要或目录,作者需要删除请E-mail邮箱bigeng88@qq.com